H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential [Yahoo! Finance]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Yahoo! Finance
Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value drivers: the platform technology RaniPill, a recent collaboration agreement with Chugai Pharmaceutical for a hemophilia product, and an additional five drug targets, as well as RT-114, which is an oral GLP-1/GLP-2 dual agonist candidate. H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential H.C. Wainwright expects data readouts on RT-114 to be the biggest driver of near-term value creation for the company's shares. A day prior, on October 20, Maxim raised the firm's price target on Rani Therapeutics to $10 from $5 with a Buy rating on the shares after the company announced the licensing deal with Chugai Pharmaceutical and a concurrent private placement to raise $60 million in proceeds. Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is a clinical-stage biotherapeutics company that
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rani Therapeutics to Participate in the Evercore Healthcare ConferenceGlobeNewswire
- Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewswire
RANI
Earnings
- 8/7/25 - Beat
RANI
Sec Filings
- 12/4/25 - Form EFFECT
- 12/3/25 - Form 424B5
- 11/25/25 - Form PRE
- RANI's page on the SEC website